Message 001
Communication from the Commission - TRIS/(2025) 2193
Directive (EU) 2015/1535
Notification: 2025/0448/LV
Notification of a draft text from a Member State
Notification – Notification – Notifzierung – Нотификация – Oznámení – Notifikation – Γνωστοποίηση – Notificación – Teavitamine – Ilmoitus – Obavijest – Bejelentés – Notifica – Pranešimas – Paziņojums – Notifika – Kennisgeving – Zawiadomienie – Notificação – Notificare – Oznámenie – Obvestilo – Anmälan – Fógra a thabhairt
Does not open the delays - N'ouvre pas de délai - Kein Fristbeginn - Не се предвижда период на прекъсване - Nezahajuje prodlení - Fristerne indledes ikke - Καμμία έναρξη προθεσμίας - No abre el plazo - Viivituste perioodi ei avata - Määräaika ei ala tästä - Ne otvara razdoblje kašnjenja - Nem nyitja meg a késéseket - Non fa decorrere la mora - Atidėjimai nepradedami - Atlikšanas laikposms nesākas - Ma jiftaħx il-perijodi ta’ dewmien - Geen termijnbegin - Nie otwiera opóźnień - Não inicia o prazo - Nu deschide perioadele de stagnare - Nezačína oneskorenia - Ne uvaja zamud - Inleder ingen frist - Ní osclaíonn sé na moilleanna
MSG: 20252193.EN
1. MSG 001 IND 2025 0448 LV EN 15-08-2025 LV NOTIF
2. Latvia
3A. Ekonomikas ministrija, T.: +371 67013100, e-pasts: notification@em.gov.lv
3B. Veselības ministrija, T.: +371 67876095, e-pasts: vm@vm.gov.lv
4. 2025/0448/LV - C00C - CHEMICALS
5. Draft Law “Amendments to the Law On the Procedures for the Coming into Force and Application of the Criminal Law”
6. Narcotic or psychotropic substances
7.
8. To control the new psychoactive substances, their derivatives, to establish control exemptions for naltrexone, methylnaltrexone and bupropion, and to supplement the list of controlled precursors, to control semi-synthetic cannabinoids. To control several substances conforming to the generic formula of 3-phenylmorpholine, as well as to determine the extent of illegal circulation of the new substances included in the draft law at national level.
9. The amendments to the law aim to control the new psychoactive substances - the synthetic opioid spirochlorphine, cychlorphine and its derivatives, and a substance of the benzodiazepine group - diclazafone desglycyl, and gamma-butyrolactone or GBL.
In addition, it is planned to establish control exemptions for naltrexone, methylnaltrexone and bupropion, to include zaleplon in the lists of controlled substances, to supplement the list of precursors with the following substances: isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate or IMDPAM, 2-methyl-3-phenyloxirane-2-carboxylic acid (BMK glycidic acid) and its ethyl, methyl, propyl, isopropyl-, butyl, isobutyl-, sec-butyl- and tert-butyl- esters, 3-(1,3-benzodioxol-5-yl)-2-methyloxirane-2-carboxylic acid (PMK glycidic acid) and its ethyl, methyl, propyl, isopropyl-, butyl, isobutyl-, sec-butyl- and tert-butyl- esters, excluding PMK ethyllicidate, BMK methyl glycidate, and PMK methyl glycidate, as well as to supplement the description of the generic groups “Dibenzopyranes” in order to explicitly control several semi-synthetic cannabinoids.
To supplement the description of the group “2-phenylmorpholines” with the description of “3-phenylmorpholines” to control several substances conforming to the generic formula of 3-phenylmorpholine that can pose a potential health risk.
The draft law also provides for the determination at national level of the extent of illegal circulation of the new substances included in the draft law, as well as for the control of several particularly dangerous substances in any amount.
10. Reference(s) to main text(s): 2024/0057/LV,2022/0129/LV,2020/0213/LV,2019/0321/LV
The primary texts were forwarded together with an earlier notification:
2024/0057/LV
2022/0129/LV
2020/0213/LV
2019/0321/LV
11. Yes
12. As the draft law includes essential aspects to protect the public health and safety by protecting the public interests and hindering the increase in the supply and demand of narcotic and psychotropic substances in Latvia, it would be important to examine the draft law according to the accelerated procedure.
As of 4 December 2024, the temporary prohibition of 8-[1-(4-chlorophenyl)ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one) or spirochlorophine established by the Centre for Disease Prevention and Control (hereinafter - SCCP) is in force and, as of 8 December 2024, the temporary prohibition of 2-amino-N-[4-chloro-2-(2-chlorobenzoyl)phenyl]acetamide or diclazafone desglycyl established by the SCCP is in force. In view of the fact that the substances which are subject of the SPKC’s decision to ban the manufacture, acquisition, storage, transport, transfer or distribution of the new psychoactive substance in question or of any products containing it, undermine the public health and safety, no later than in 12 months from the date of entry into force of the decision, the respective substances must be subjected to continuous control in Annex 2 to the law to prevent the substance from returning to uncontrolled circulation.
13. No
14. No
15. Yes
16.
TBT aspects: No
SPS aspects: No
**********
European Commission
Contact point Directive (EU) 2015/1535
email: grow-dir2015-1535-central@ec.europa.eu
